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Abstract
Background: Myasthenia gravis is an autoimmune neuromuscular disorder, which has only rarely been reported to
co-manifest with myositis. The diagnosis of concomitant myositis in patients with myasthenia gravis is clinically
challenging, and requires targeted investigations for the differential diagnosis, including EMG, autoantibody assays,
muscle biopsy and, importantly, imaging of the mediastinum for thymoma screening.
Case presentation: This report presents a case-vignette of a 72-year-old woman with progressive proximal muscle
weakness and myalgias, diagnosed with thymoma-associated myasthenia and bioptically verified granulomatous
myositis, with positive autoantibody status for ryanodine receptor and titin antibodies.
Conclusions: The diagnosis of concurrent myositis and myasthenia gravis, especially in the presence of ryanodine
receptor and titin antibodies, should lead neurologists to adopt different treatment strategies compared to those
applied in myasthenia or myositis alone. Moreover, further evidence is warranted that titin and, particularly,
ryanodine receptor antibodies may co-occur or be pathophysiologically involved in myasthenia-myositis cases.
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Background
Myasthenia gravis (MG) is an organ-specific, autoimmune
disorder, which is generally mediated by anti-acetylcholine
receptor (AChR) or, less frequently, by anti-muscle-specific
receptor tyrosine kinase (MuSK) antibodies (Ab) at the
neuromuscular junction [1]. Striational-Ab, reacting with
epitopes on muscle proteins and binding in a cross-
striational pattern to skeletal and heart muscle tissue sec-
tions, have also been associated with severe, late-onset or
thymoma-associated MG cases [2, 3]. Two major antigens
for striational-Ab are: a) titin, a gigantic filamentous
muscle protein, basically involved in muscle function,
structure and development, and b) ryanodine receptor
(RyR), a Ca2+ release channel of the sarcoplasmic
reticulum, essential for the excitation-contraction coupling
in striated muscle [4]. Titin-Ab and RyR-Ab are deter-
mined by enzyme-linked immunosorbent assay or immu-
noblot, and have been recently detected in first cases of
thymoma-MG with co-manifesting myositis [5]. Al-
though MG has been repeatedly associated with many
autoimmune disorders, reports of patients with con-
comitant manifestation of MG-myositis are seldom
[6–8]. Consequently, further evidence is warranted
that titin-Ab and, particularly, RyR-Ab may be associ-
ated with MG-myositis cases.
Case presentation
A 72-year-old woman presented with 4 weeks of pro-
gressive, non-fluctuating, proximal muscle weakness and
myalgia, after an acute manifestation of dysarthria. She
complained of prominent fatigue and difficulty climbing
stairs without assistance. In the family history no neuro-
logical disorders were reported. On physical examination,
the patient had a moderate bilateral ptosis with positive
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test of eyelid fatigability, and a proximally accentuated
muscle weakness in all extremities (grade 4/5 MRC in arm
abductors, elbow extensors and hip flexors). Serological
examination showed normal creatine kinase levels (70 U/l).
Brain MRI presented no signs of cerebrovascular etiology
of the acutely manifested dysarthria. Needle-EMG showed
marked, pathological spontaneous activity (fibrillations and
positive sharp waves) with complex, repetitive, pseudo-
myotonic discharges. In addition, muscle ultrasound re-
vealed increased muscle echogenicity with prominent
vascularization, suggestive of an active inflammatory
myopathy. No decrement on 3Hz repetitive nerve stimula-
tion was noted. A right deltoid muscle biopsy demonstrated
endomysial CD68-immunoreactive giant cells and macro-
phages (Fig. 1), leading to the diagnosis of a granulomatous
myositis (GrM). Furthermore, immunoassay analysis
showed a high titer of AChR-Ab (142 nmol/l) and positive
results for titin-Ab and RyR-Ab. No MuSK-Ab or other
myositis-associated autoantibodies were detected. Malig-
nancy screening, including chest CT, revealed a mediastinal
mass suggestive of thymoma. In the chest CT scan, no pul-
monary or mediastinal evidence of sarcoidosis was noted;
additionally, the serum concentrations of angiotensin-
converting enzyme (ACE) and soluble IL2 receptor
(sIL2R) were normal. A video-assisted thoracoscopic
thymectomy was performed, and pathological analysis
disclosed a type AB, noninvasive (Masaoka stage I)
thymoma. The patient was respectively diagnosed with
thymoma-associated MG and GrM, and treatment with
pyridostigmine, prednisone (initially 20 mg/d, increased
to 60 mg/d after a week, and gradually tapered over
3 months), and azathioprine (75 mg/d) was initiated.
Under the combined treatment regime, a marked
improvement of her muscle strength was noted, with
complete clinical remission after 3 months. Corresponding
with this marked clinical improvement, repeated immuno-
assay analyses showed a progressive decline of AChR-Ab
titer (23 nmol/l after 1 month, 7.55 nmol/l at 3 months),
normalization of titin-Ab (negative at 3 months) and
decline of RyR-Ab (lower reactivity in the immunoassay
at 3 months).
Conclusions
This report presents a case of histologically verified GrM
and thymoma - associated MG with positive AChR-Ab,
titin-Ab and RyR-Ab. GrM is a rare, inflammatory neuro-
muscular disorder, histologically characterized by the devel-
opment of non-specific, epithelioid granulomas in striated
muscle. Although a well-established association between
GrM and sarcoidosis exists in the literature, GrM may ac-
company a wide spectrum of inflammatory and infectious
diseases [9]. Interestingly, a concomitant manifestation of
GrM with thymoma-MG is extremely rare [7, 8, 10]. The
clinical hallmarks of GrM involve generalized muscle weak-
ness, myalgias, and bulbar symptoms. Upon clinical suspi-
cion of GrM, targeted procedures are warranted, including:
a) investigation of muscular enzymes; these are commonly
normal in the majority of GrM patients, yet, mild to high
elevations have also been reported [9], b) imaging and la-
boratory investigations to assess muscle inflammatory pro-
cesses, or to evaluate other organ affection when comorbid
sarcoidosis is suspected (ACE and sIL2R were negative in
this case), c) EMG testing, and d) pathological studies,
which are mandatory for a definite diagnosis of GrM [9].
Conversely, in respect to the clinical manifestation,
intermittent diplopia, ptosis and fluctuating muscle
Fig. 1 Granulomatous Myositis (deltoid muscle biopsy, hematoxylin and eosin staining). Abundant muscle infiltration with inflammatory cells and
multinucleate giant cells. Inset: Giant cell expressing the macrophage marker CD68
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fatigability are classic features of MG, but are virtually
never encountered in patients with myositis alone [6].
Given the partly overlapping symptoms of the two disor-
ders, a co-manifesting GrM in patients with MG is likely
to remain underdiagnosed. Yet, the presence of ‘red-flag’
features, such as a history of permanent, non-fluctuating
muscle weakness, should lead physicians to consider
comorbid myositis in MG patients. Imaging of the medias-
tinum is, importantly, recommended in all newly diag-
nosed cases of MG. Furthermore, electrophysiological
studies, antibody assays, and muscle biopsy - even if the
muscular enzymes are normal - are required for the differ-
ential diagnosis.
In particular, we suggest that myositis/MG -Ab investi-
gations should include titin-Ab and RyR-Ab screening.
Titin-Ab and RyR-Ab have a 70 % positive predictive
value, and 95 % sensitivity and specificity for a thymoma
in MG [4]. These striational antibodies have been repeat-
edly associated with thymoma-MG or severe, late-onset
MG cases; nevertheless, their pathogenetic role in dis-
ease processes has, yet, not been clearly elucidated [11].
On the other hand, a broad spectrum of autoimmune
disorders, and corresponding autoantibodies, have been
related to thymoma [12]. The link between thymoma and
autoimmunity probably indicates disrupted immunological
surveillance mechanisms as a result of thymic dysfunction
[12]. Thus, the occurrence of striational antibodies in
thymoma-related GrM-MG cases may, to a certain extent,
also reflect thymic dysfunction per se [12]. Additional evi-
dence by future larger studies is warranted to investigate
whether titin-Ab and RyR-Ab are frequently detected
among MG-myositis patients, and whether the presence of
these antibodies may suggest an underlying thymoma in
the MG-myositis patient group.
Detecting the coincidence of MG and GrM is im-
portant, as in such cases different treatment strategies
may be indicated. Considering that titin-Ab and RyR-
Ab have been mostly associated with invasive/malig-
nant types of thymoma, in the presence of such anti-
bodies in MG or GrM-MG patients, the employment
of a thymectomy technique that assures complete re-
section is decisive for the prognosis [4]. Lastly, given
that in patients with MG - in contrast to myositis - ini-
tiation of therapy with high-dose steroids may exacer-
bate muscle weakness, in cases with concomitant
manifestation of both disorders, a low-dose initiation of
steroids with gradual titration, and concurrent administra-
tion of anticholinesterase agents, such as pyridostigmine,
should be considered [6].
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